AU2017316618A1 - Combination therapy for the treatment of pancreatic cancer - Google Patents

Combination therapy for the treatment of pancreatic cancer Download PDF

Info

Publication number
AU2017316618A1
AU2017316618A1 AU2017316618A AU2017316618A AU2017316618A1 AU 2017316618 A1 AU2017316618 A1 AU 2017316618A1 AU 2017316618 A AU2017316618 A AU 2017316618A AU 2017316618 A AU2017316618 A AU 2017316618A AU 2017316618 A1 AU2017316618 A1 AU 2017316618A1
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
inhibitor
geneid
cobimetinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017316618A
Other languages
English (en)
Inventor
Nisebita SAHU
Jeff SETTLEMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2017316618A1 publication Critical patent/AU2017316618A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017316618A 2016-08-23 2017-08-22 Combination therapy for the treatment of pancreatic cancer Abandoned AU2017316618A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378322P 2016-08-23 2016-08-23
US62/378,322 2016-08-23
PCT/US2017/047985 WO2018039211A1 (en) 2016-08-23 2017-08-22 Combination therapy for the treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
AU2017316618A1 true AU2017316618A1 (en) 2019-02-07

Family

ID=59762090

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017316618A Abandoned AU2017316618A1 (en) 2016-08-23 2017-08-22 Combination therapy for the treatment of pancreatic cancer

Country Status (11)

Country Link
US (2) US10933058B2 (enExample)
EP (1) EP3503922B1 (enExample)
JP (2) JP7579636B2 (enExample)
KR (1) KR20190039951A (enExample)
CN (1) CN109641058A (enExample)
AU (1) AU2017316618A1 (enExample)
BR (1) BR112019002945A2 (enExample)
CA (1) CA3034259A1 (enExample)
IL (1) IL264589A (enExample)
MX (1) MX2019002121A (enExample)
WO (1) WO2018039211A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190039951A (ko) * 2016-08-23 2019-04-16 제넨테크, 인크. 췌장암의 치료를 위한 병용요법
US20210220471A1 (en) * 2018-07-13 2021-07-22 Memorial Sloan Kettering Cancer Center Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer
CA3186465A1 (en) * 2019-10-22 2021-04-29 Chemistry Rx Methods for treating congenital epidermal hyperplasia
CN115243719B (zh) * 2020-03-06 2024-09-13 北京先通生物医药技术有限公司 CTB006与Ponatinib联合应用
CN115813930B (zh) * 2021-08-17 2026-05-26 赛诺哈勃药业（成都）有限公司 大环化合物与mek抑制剂联用在用于治疗疾病药物中的用途
CN116509852B (zh) * 2023-04-30 2026-07-31 兰州大学第二医院 含zinc218238819化合物的胰腺癌jak2和stat3双靶向抑制剂及应用
CN116585312B (zh) * 2023-04-30 2026-07-31 兰州大学第二医院 含苯氧基丙酸化合物的胰腺癌jak2和stat3双靶向抑制剂及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015175846A2 (en) * 2014-05-16 2015-11-19 University Of Massachusetts Treating chronic myelogenous leukemia (cml)
WO2016123054A2 (en) * 2015-01-26 2016-08-04 The University Of North Carolina At Chapel Hill Kinase drug combinations and methods of use thereof
WO2016130917A1 (en) * 2015-02-12 2016-08-18 Memorial Sloan Kettering Cancer Center Synergistic cancer treatment
KR20190039951A (ko) * 2016-08-23 2019-04-16 제넨테크, 인크. 췌장암의 치료를 위한 병용요법

Also Published As

Publication number Publication date
CN109641058A (zh) 2019-04-16
JP7579636B2 (ja) 2024-11-08
KR20190039951A (ko) 2019-04-16
MX2019002121A (es) 2019-08-12
US12419879B2 (en) 2025-09-23
IL264589A (en) 2019-02-28
CA3034259A1 (en) 2018-03-01
US10933058B2 (en) 2021-03-02
US20190175576A1 (en) 2019-06-13
JP2024170398A (ja) 2024-12-10
BR112019002945A2 (pt) 2019-05-21
WO2018039211A1 (en) 2018-03-01
EP3503922A1 (en) 2019-07-03
US20210283120A1 (en) 2021-09-16
EP3503922B1 (en) 2022-10-26
JP2019526559A (ja) 2019-09-19

Similar Documents

Publication Publication Date Title
US12419879B2 (en) Combination therapy for the treatment of pancreatic cancer
ES3033810T3 (en) Cancer treatments using combinations of cdk and erk inhibitors
Yan et al. Aurora‐A kinase: a potent oncogene and target for cancer therapy
AU2016287507B2 (en) Methods of treating hematological malignancy using nanoparticle mTOR inhibitor combination therapy
ES3059018T3 (en) Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors
Saha et al. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa
US20200253979A1 (en) Therapeutic methods relating to hsp90 inhibitors
US10111897B2 (en) Compositions and methods for treating cancer with JAK2 activity
JP2022082565A (ja) がんを処置するための方法
ES2992827T3 (en) Combination therapies targeting mitochondrial biogenesis for cancer therapy
US20140348819A1 (en) Methods of Treating Cancer
WO2021262962A1 (en) Methods for treating cancer with combination therapies
Pan et al. STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRASG12C Inhibitors in Nonsmall Cell Lung Cancer
WO2021099558A1 (en) Combination therapies
EP2827903A1 (en) Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition
WO2021013794A1 (en) Transcriptomics for selecting druggable targets for combination therapy in cancer
US20240398814A1 (en) Kras inhibitor and hdac inhibitor combination for the treatment of cancer
HK40001148A (en) Combination therapy for the treatment of pancreatic cancer
WO2023192291A2 (en) Indolium compounds for treating cancer
Langdon Combination high throughput compound screening for melanoma and lung adenocarcinoma

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period